Naomi Rosenberg, Ph.D., is Dean of the Sackler School of Graduate Biomedical Sciences at Tufts University and Vice Dean for Research and Professor of Pathology at Tufts University School of Medicine. Dr. Rosenberg oversees Tufts University’s efforts to solve problems of biomedical importance that span the translational spectrum from the most basic to bench-to-bedside scientific research and beyond, as well as the education and training of the next generation of highly educated biomedical scientists. A microbiologist by training, Dr. Rosenberg’s research career has focused on investigating the ways cancer develops. She developed the first tractable model to study leukemia development in vitro, in vitro, using the Abelson murine leukemia virus; her work paved the way for identification of the abl oncogene and the discovery that this oncogene is responsible for human chronic myelogenous leukemia (CML). These findings were central to the development of imantinib, a drug used to treat CML, and played a major role in experiments that led to understanding the basic process whereby genes are rearranged so that antibody molecules can be produced, a critical step in the immune response. At the national level, she has served on numerous federal committees, including the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health; the Board of Scientific Counselors of the National Cancer Institute; the Board of Directors of the Leukemia and Lymphoma Society of America; and the Advisory Committee to the NIH Director Working Group on the Future Biomedical Workforce. She currently serves on the Biosafety Working Group of the RAC and is the chair elect of the Graduate Education and Research Training Group of the American Association of Medical Colleges.
Dr. Rosenberg can speak about:
- Biomedical research